BOARD OF DIRECTORS
ACUTE SUICIDAL IDEATION/BEHAVIOR (ASIB) IN BIPOLAR DEPRESSION
PATIENT STORIES THAT INSPIRE US
MECHANISM OF ACTION
IN THE NEWS
NeuroRx announces FDA IND clearance for NRX-101 phase 2b/3 study and publication of promising biomarker data
View the Press Release!
Neurorx, inc. is a clinical stage, small molecule pharmaceutical company developing novel therapeutics for the treatment of central nervous system disorders
The first oral therapeutic being developed for the treatment of acute suicidal crisis in bipolar disorder
Recent scientific breakthroughs suggest the chemical target for suicidality in bipolar depression may be localized in the brain’s NMDA receptor
View the latest press releases and media coverage for NeuroRx
© 2016 NeuroRx, Inc.
*This drug is investigational and not approved by the US FDA